Best known globally for its aspirin and locally for its life-saving hemophilia treatments, drug giant Bayer is firming up plans to lead one of biotech's hottest areas with a pioneering new cell therapy manufacturing facility on its fast-changing Berkeley campus.
The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
In the United States, the summer of 2025 will be remembered as artificial intelligence’s (AI’s) cruel summer—a season when the unheeded risks and dangers of AI became undeniably clear. Recent months have made visible the stakes of the unchecked use...
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Aggregated News
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...
By Auriane Polge, Science & Vie [cites CGS' Katie Hasson] | 09.19.2025
Aggregated News
L’idée de pouvoir choisir certaines caractéristiques de son futur enfant a longtemps relevé de la science-fiction ou du débat éthique. Aujourd’hui, les technologies de séquençage et les algorithmes d’analyse génétique repoussent les limites de ce qui semblait encore impossible. Au croisement...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.